Compare Moody's Corporation (MCO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs TransMedics Group Inc — how do they compare? Moody's Corporation trades at $476.73 (market cap $82.52B), while TransMedics Group Inc trades at $87.58 (market cap $3.10B). The key difference: Moody's Corporation is far larger — about 26.6× TransMedics Group Inc's market cap, and Moody's Corporation pays a 0.86% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MCO | TMDX | |
|---|---|---|
Market Cap | $82.52B | $3.10B |
Sector | Financials | Technology |
52-Week High | $539.61 | $150.42 |
52-Week Low | $412.23 | $61.99 |
Enterprise Value | $88.54B | $3.49B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $477.84, showing minimal daily movement (-0.06%) amid a bearish technical signal. The company demonstrates strong fundamentals with 15% revenue growth in Q2 2026 and consistent earnings beats, achieving a 34.25% net income margin. Recent news highlights institutional repositioning into credit rating companies, with MCO benefiting from robust debt issuance and AI-related analytics demand.
Outlook remains positive with a $561.88 consensus price target (17.6% upside), though valuation multiples appear elevated. Key risks include competitive pressures and market sensitivity to credit cycles. The combination of strong profitability, analyst support (56% buy ratings), and strategic positioning in credit analytics supports a constructive view despite technical headwinds.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
